Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.65 |
| ▸ | AURKA | O14965 | 3/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.43 |
| ▸ | BRAF | P15056 | 3/20 | 0.43 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | MET | P08581 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5272019 | 0.90 | CHEK1 (0.52) | CHEK1AURKAAURKBBRAFSIGMAR1 | |
| Hydrochloric Acid SCHEMBL5493932 | 0.88 | CHEK1 (0.60) | CHEK1AURKAAURKBBRAFTNNI3K | |
| SCHEMBL5278912 | 0.86 | CHEK1 (0.68) | CHEK1AURKAAURKBBRAFTNNI3K | |
| Hydrochloric Acid SCHEMBL5499642 | 0.85 | CHEK1 (0.67) | CHEK1AURKAAURKBBRAFTNNI3K | |
| SCHEMBL5280709 | 0.84 | CHEK1 (0.67) | CHEK1AURKAAURKBBRAFTNNI3K | |
| Hydrochloric Acid SCHEMBL5498930 | 0.84 | CHEK1 (0.66) | CHEK1AURKAAURKBBRAFTNNI3K | |
| SCHEMBL7206444 | 0.82 | CHEK1 (0.77) | CHEK1AURKAAURKBBRAFTNNI3K | |
| Hydrochloric Acid SCHEMBL5499449 | 0.82 | CHEK1 (0.71) | CHEK1AURKAAURKBBRAFTNNI3K | |
| Hydrochloric Acid SCHEMBL5500537 | 0.81 | CHEK1 (0.41) | CHEK1EGFRHRH3 | |
| SCHEMBL5272907 | 0.81 | CHEK1 (0.41) | CHEK1METKDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458395-B1 | MEDICAL USE OF GSK3-INHIBITING OXINDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-11-28 | — | — | EP | claimed |
| EP-1005470-B1 | OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2007-08-01 | — | — | EP | claimed |
| US-20050075351-A1 | Use | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | US | claimed |
| EP-1458395-A1 | NEW USE | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003053444-A1 | NEW USE | ASTRAZENECA AB (SE) | 2003-07-03 | — | — | WO | claimed |
| US-6294532-B1 | TREATMENT OF A NUMBER OF DISEASE STATES INCLUDING CANCER AND RHEUMATOID ARTHRITIS. | ZENECA LIMITED (GB) | 2001-09-25 | — | — | US | claimed |
| EP-1005470-A1 | OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ZENECA LIMITED (GB) | 2000-06-07 | — | — | EP | claimed |
| WO-1999010349-A1 | OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ZENECA LIMITED (GB) | 1999-03-04 | — | — | WO | claimed |
| EP-1458395-B1 | MEDICAL USE OF GSK3-INHIBITING OXINDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-11-28 | — | — | EP | disclosed |
| EP-1005470-B1 | OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2007-08-01 | — | — | EP | disclosed |
| US-20050075351-A1 | Use | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | US | disclosed |
| EP-1458395-A1 | NEW USE | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003053444-A1 | NEW USE | ASTRAZENECA AB (SE) | 2003-07-03 | — | — | WO | disclosed |
| US-6294532-B1 | TREATMENT OF A NUMBER OF DISEASE STATES INCLUDING CANCER AND RHEUMATOID ARTHRITIS. | ZENECA LIMITED (GB) | 2001-09-25 | — | — | US | disclosed |
| EP-1005470-A1 | OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ZENECA LIMITED (GB) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010349-A1 | OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ZENECA LIMITED (GB) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075351-A1 | Use | GSK3A, GSK3B, PYGB | CHEK1 1639/4885AURKA 775/4885AURKB 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.